Validation of co-SSPedi: a novel dyadic approach to symptom screening in pediatric patients receiving cancer treatment
Menée auprès de 501 dyades constituées d'un aidant et d'un patient pédiatrique atteint d'un cancer ou recevant une greffe de cellules souches hématopoïétiques (âge : 4-18 ans), cette étude évalue l'intérêt d'un outil permettant de déclarer les symptômes pendant et après les traitements
Résumé en anglais
Background: Co-Symptom Screening in Pediatrics Tool (co-SSPedi) is a dyadic (child-guardian) approach to symptom assessment. Objectives were to evaluate the reliability and validity of co-SSPedi for pediatric patients receiving cancer treatments.
Methods: This multi-center study included dyads of patients 4-18 years of age with cancer or undergoing hematopoietic cell transplant (HCT), and their guardians. Two groups were enrolled. More symptomatic group included those receiving active treatment for cancer or undergoing HCT where patients were in hospital/clinic for four consecutive days. Less symptomatic group included those receiving maintenance therapy for acute lymphoblastic leukemia or had completed cancer treatments. At baseline, all dyads completed co-SSPedi and guardians completed measures of mucositis, nausea, pain, quality of life and overall symptoms. In the more symptomatic group, dyads completed co-SSPedi and a global symptom change scale on day 4.
Results: There were 501 dyads included, 301 in the more symptomatic group and 200 in the less symptomatic group. Median time to complete co-SSPedi was less than three minutes in both groups. Test-retest reliability intraclass correlation coefficient (ICC) was 0.85 (95% confidence interval (CI) 0.77-0.90). For internal consistency, total co-SSPedi Cronbach’s alpha was 0.81 (95% CI 0.78-0.83). For known groups validation, mean difference in total co-SSPedi scores between the more symptomatic and less symptomatic groups was 7.8 (95% CI 6.7-8.8, P < 0.0001). For convergent validation and responsiveness, all hypothesized relationships were demonstrated.
Conclusions: Co-SSPedi is a novel approach to dyadic symptom assessment that is reliable, valid and responsive in pediatric patients 4 to 18 years of age.
